DaVita (DVA) Q3 2026 Earnings Call Transcript
DaVita (DVA) Q3 2026 Earnings Call Transcript（摘要待生成）
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Yahoo Finance
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Yahoo Finance（摘要待生成）
CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement
CorMedix shares reached a 52-week low after DaVita's CFO indicated that Medicare add-on payments for the DefenCath catheter lock solution are expected to decline significantly starting in the second quarter of 2027.
DaVita Inc. 3rd Quarter 2026 Results
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026:... The post DaVita Inc. 3rd Quarter 2026 Results appeared first on Investor.
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with... The post DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health R
DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice
DaVita today issued the following statement in response to the U.S. Department of Health and Human Services' Kidney Care National Plan and related remarks regarding the future of kidney care:... The post DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and
DaVita said DefenCath’s post-TDAPA reimbursement could fall significantly in 2027
On October 29, DaVita said the DefenCath post-TDAPA add-on payment is recalculated quarterly using volume and ASP, and its current expectation is that the amount will drop significantly from Q1 to Q2 2027, then remain low or decline through H2 2027. On October 30, CRMD fell 25.46% to $5.70, its 52-week low; the cited sources do not establish how much of the move was attributable to this warning.
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call
DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time. The company... The post DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call appeared first on Investor.
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/... The post DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next